Max Robotics — Global Service Robot Directory + US Certification

About

Ryoma Kurahashi is a urologic surgeon and researcher whose work centers on optimizing surgical outcomes in robot-assisted radical prostatectomy (RARP) for prostate cancer. His major contributions focus on three key areas: mitigating bleeding complications, understanding the impact of patient age on surgical recovery, and refining oncologic strategies for high-risk disease. In a pivotal 2024 cohort study, Kurahashi demonstrated that thienopyridine-class antiplatelet agents (ticlopidine, clopidogrel, prasugrel) significantly increase bleeding risks during RARP, providing critical guidance for perioperative medication management—work that has already garnered 7 citations. He further showed that aging independently predicts higher complication rates after RARP, informing preoperative counseling. For high-risk patients, Kurahashi has explored the therapeutic value of extended pelvic lymph node dissection (ext-LDN) in a large multi-institutional analysis of 8,194 cases, and investigated neoadjuvant chemohormonal therapy using GnRH antagonists with low-dose estramustine to reduce biochemical recurrence. His research on neurovascular bundle preservation in high-risk disease also challenges conventional boundaries of nerve-sparing surgery. With multiple 2024–2025 publications accumulating citations rapidly, Kurahashi is establishing himself as a rising authority in robotic urologic oncology, directly shaping evidence-based protocols for complex prostate cancer surgery.